PT  - JOURNAL ARTICLE
AU  - Dorling, Leila
AU  - Carvalho, Sara
AU  - Allen, Jamie
AU  - Parsons, Michael T.
AU  - Fortuno, Cristina
AU  - González-Neira, Anna
AU  - Heijl, Stephan M.
AU  - Adank, Muriel A.
AU  - Ahearn, Thomas U.
AU  - Andrulis, Irene L.
AU  - Auvinen, Päivi
AU  - Becher, Heiko
AU  - Beckmann, Matthias W.
AU  - Behrens, Sabine
AU  - Bermisheva, Marina
AU  - Bogdanova, Natalia V.
AU  - Bojesen, Stig E.
AU  - Bolla, Manjeet K.
AU  - Bremer, Michael
AU  - Briceno, Ignacio
AU  - Camp, Nicola J.
AU  - Campbell, Archie
AU  - Castelao, Jose E.
AU  - Chang-Claude, Jenny
AU  - Chanock, Stephen J.
AU  - Chenevix-Trench, Georgia
AU  - ,
AU  - Collée, J. Margriet
AU  - Czene, Kamila
AU  - Dennis, Joe
AU  - Dörk, Thilo
AU  - Eriksson, Mikael
AU  - Evans, D. Gareth
AU  - Fasching, Peter A.
AU  - Figueroa, Jonine
AU  - Flyger, Henrik
AU  - Gabrielson, Marike
AU  - Gago-Dominguez, Manuela
AU  - García-Closas, Montserrat
AU  - Giles, Graham G.
AU  - Glendon, Gord
AU  - Guénel, Pascal
AU  - Gündert, Melanie
AU  - Hadjisavvas, Andreas
AU  - Hahnen, Eric
AU  - Hall, Per
AU  - Hamann, Ute
AU  - Harkness, Elaine F.
AU  - Hartman, Mikael
AU  - Hogervorst, Frans B.L.
AU  - Hollestelle, Antoinette
AU  - Hoppe, Reiner
AU  - Howell, Anthony
AU  - ,
AU  - ,
AU  - Jakubowska, Anna
AU  - Jung, Audrey
AU  - Khusnutdinova, Elza
AU  - Kim, Sung-Won
AU  - Ko, Yon-Dschun
AU  - Kristensen, Vessela N.
AU  - Lakeman, Inge M.M.
AU  - Li, Jingmei
AU  - Lindblom, Annika
AU  - Loizidou, Maria A.
AU  - Lophatananon, Artitaya
AU  - Lubiński, Jan
AU  - Luccarini, Craig
AU  - Madsen, Michael J.
AU  - Mannermaa, Arto
AU  - Manoochehri, Mehdi
AU  - Margolin, Sara
AU  - Mavroudis, Dimitrios
AU  - Milne, Roger L.
AU  - Mohd Taib, Nur Aishah
AU  - Muir, Kenneth
AU  - Nevanlinna, Heli
AU  - Newman, William G.
AU  - Oosterwijk, Jan C.
AU  - Park, Sue K.
AU  - Peterlongo, Paolo
AU  - Radice, Paolo
AU  - Saloustros, Emmanouil
AU  - Sawyer, Elinor J.
AU  - Schmutzler, Rita K.
AU  - Shah, Mitul
AU  - Sim, Xueling
AU  - Southey, Melissa C.
AU  - Surowy, Harald
AU  - Suvanto, Maija
AU  - Tomlinson, Ian
AU  - Torres, Diana
AU  - Truong, Thérèse
AU  - van Asperen, Christi J.
AU  - Waltes, Regina
AU  - Wang, Qin
AU  - Yang, Xiaohong R.
AU  - Pharoah, Paul D.P.
AU  - Schmidt, Marjanka K.
AU  - Benitez, Javier
AU  - Vroling, Bas
AU  - Dunning, Alison M.
AU  - Teo, Soo Hwang
AU  - Kvist, Anders
AU  - de la Hoya, Miguel
AU  - Devilee, Peter
AU  - Spurdle, Amanda B.
AU  - Vreeswijk, Maaike P.G.
AU  - Easton, Douglas F.
TI  - Breast cancer risks associated with missense variants in breast cancer susceptibility genes
AID  - 10.1101/2021.09.02.21262369
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.02.21262369
4099  - http://medrxiv.org/content/early/2021/09/15/2021.09.02.21262369.short
4100  - http://medrxiv.org/content/early/2021/09/15/2021.09.02.21262369.full
AB  - BACKGROUND Protein truncating variants in ATM, BRCA1, BRCA2, CHEK2 and PALB2 are associated with increased breast cancer risk, but risks associated with missense variants in these genes are uncertain.METHODS Combining 59,639 breast cancer cases and 53,165 controls, we sampled training (80%) and validation (20%) sets to analyze rare missense variants in ATM (1,146 training variants), BRCA1 (644), BRCA2 (1,425), CHEK2 (325) and PALB2 (472). We evaluated breast cancer risks according to five in-silico prediction-of-deleteriousness algorithms, functional protein domain, and frequency, using logistic regression models and also mixture models in which a subset of variants was assumed to be risk-associated.RESULTS The most predictive in-silico algorithms were Helix (BRCA1, BRCA2 and CHEK2) and CADD (ATM). Increased risks appeared restricted to functional protein domains for ATM (FAT and PIK domains) and BRCA1 (RING and BRCT domains). For ATM, BRCA1 and BRCA2, data were compatible with small subsets (approximately 7%, 2% and 0.6%, respectively) of rare missense variants giving similar risk to those of protein truncating variants in the same gene. For CHEK2, data were more consistent with a large fraction (approximately 60%) of rare missense variants giving a lower risk (OR 1.75, 95% CI (1.47-2.08)) than CHEK2 protein truncating variants. There was little evidence for an association with risk for missense variants in PALB2. The best fitting models were well calibrated in the validation set.CONCLUSIONS These results will inform risk prediction models and the selection of candidate variants for functional assays, and could contribute to the clinical reporting of gene panel testing for breast cancer susceptibility.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe sequencing and analysis for this project was funded by the European Union's Horizon 2020 Research and Innovation Programme (BRIDGES: grant number 634935) and the Wellcome Trust [grant no: v203477/Z/16/Z]. BCAC co-ordination was additionally funded by the European Union's Horizon 2020 Research and Innovation Programme (BRIDGES: grant number 634935, BCAST: grant number 633784) and by Cancer Research UK [C1287/A16563]. Study specific funding is given in the Supplemental Note. No authors received payment or services from a third party for any aspect of the submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval to use the BCAC data included in this study was given by the Data Access Co-ordinating Committee (concept #672). All contributing BCAC studies were approved by the relevant ethical review boards, details of which can be found in Additional Table 14.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary level genotype data are available via http://bcac.ccge.medschl.cam.ac.uk and in Supplementary Tables 9-13. Individual level data are available via the BCAC Data Access Co-ordinating Committee (bcac@medschl.cam.ac.uk)PTVsProtein truncating variantsVUSVariants of uncertain significanceBCACBreast Cancer Association ConsortiumVEPEnsembl Variant Effect PredictorCADDCombined Annotation Dependent DepletionREVELRare Exome Variant Ensembl LearnerSGESaturation Genome EditingLRLogistic regressionOROdds ratioEMExpectation-maximizationPPPosterior probabilityQ5Fifth quntileLOFSGELoss of functionFUNCSGEFunctionalINTSGEIntermediate functionGWASGenome wide association study